Background: Moderate preterms (32-35 +6 weeks gestation) are at risk for developmental delay compared to fullterms. It is unknown if postnatal complications are associated with developmental delay for this group.
AbstractsMethods Participants. 362 infants aged 10-24 months, with at least one of: weight < 1500g, < 34 completed weeks gestational age, 5-min Apgar < 7, HIE. Children with impairments preventing fair assessment by ERIC were excluded. Parents/caregivers completed ERIC at home before administration of the Cognitive Scale of the Bayley Scales of Infant Development III. Delay was defined as a prematurity-corrected Bayley score < 80 (Moore et al, 2011 James Cook University, Middlesbrough, UK Background The Cryotherapy for Retinopathy of Prematurity Cooperative Group showed that the severity of ROP was a marker for functional disability at 5.5 years in infants ≤1250 g BW who were born in the late 1980s. Objective To determine whether severe ROP remains a strong predictor of visual and non-visual disabilities at age 5 years in infants ≤1250 g BW who were enrolled in the CAP trial between 1999 and 2004.Methods 5-year follow up of 1580 surviving CAP children with known ROP status. Severe ROP was defined as stage 4 or 5 disease or receipt of retinal therapy in at least one eye. Outcomes were disabilities in 6 domains, and including cognitive impairment (Full Scale IQ< 70), motor impairment (GMFCS level 2-5), deafness and blindness. Odds ratios were adjusted for antenatal steroids, gestational age, sex, multiple birth, and mother's education. Results There were 94 survivors with and 1486 without severe ROP. Rates of visual and non-visual disabilitites were significantly higher in children with severe ROP (Table 1).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.